Metformin-associated lactic acidosis

Current perspectives on causes and risk

Ralph A Defronzo, G. Alexander Fleming, Kim Chen, Thomas A. Bicsak

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Although metformin has become a drug of choice for the treatment of type 2 diabetes mellitus, some patients may not receive it owing to the risk of lactic acidosis. Metformin, along with other drugs in the biguanide class, increases plasma lactate levels in a plasma concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver. Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin-associated lactic acidosis (MALA). As these secondary events may be unpredictable and the mortality rate for MALA approaches 50%, metformin has been contraindicated in moderate and severe renal impairment since its FDA approval in patients with normal renal function or mild renal insufficiency to minimize the potential for toxic metformin levels and MALA. However, the reported incidence of lactic acidosis in clinical practice has proved to be very low (<10 cases per 100,000 patient-years). Several groups have suggested that current renal function cutoffs for metformin are too conservative, thus depriving a substantial number of type 2 diabetes patients from the potential benefit of metformin therapy. On the other hand, the success of metformin as the first-line diabetes therapy may be a direct consequence of conservative labeling, the absence of which could have led to excess patient risk and eventual withdrawal from the market, as happened with earlier biguanide therapies. An investigational delayed-release metformin currently under development could potentially provide a treatment option for patients with renal impairment pending the results of future studies. This literature-based review provides an update on the impact of renal function and other conditions on metformin plasma levels and the risk of MALA in patients with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)20-29
Number of pages10
JournalMetabolism: Clinical and Experimental
Volume65
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Lactic Acidosis
Metformin
Kidney
Type 2 Diabetes Mellitus
Biguanides
Lactic Acid
Product Recalls and Withdrawals
Poisons
Therapeutics
Secondary Prevention
Pharmaceutical Preparations
Renal Insufficiency

Keywords

  • Drug mechanism
  • Lactic acidosis
  • MALA
  • Metformin
  • Renal impairment

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Metformin-associated lactic acidosis : Current perspectives on causes and risk. / Defronzo, Ralph A; Fleming, G. Alexander; Chen, Kim; Bicsak, Thomas A.

In: Metabolism: Clinical and Experimental, Vol. 65, No. 2, 01.02.2016, p. 20-29.

Research output: Contribution to journalArticle

Defronzo, Ralph A ; Fleming, G. Alexander ; Chen, Kim ; Bicsak, Thomas A. / Metformin-associated lactic acidosis : Current perspectives on causes and risk. In: Metabolism: Clinical and Experimental. 2016 ; Vol. 65, No. 2. pp. 20-29.
@article{b0266c08bc7046e59e04f1f292af4e1e,
title = "Metformin-associated lactic acidosis: Current perspectives on causes and risk",
abstract = "Although metformin has become a drug of choice for the treatment of type 2 diabetes mellitus, some patients may not receive it owing to the risk of lactic acidosis. Metformin, along with other drugs in the biguanide class, increases plasma lactate levels in a plasma concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver. Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin-associated lactic acidosis (MALA). As these secondary events may be unpredictable and the mortality rate for MALA approaches 50{\%}, metformin has been contraindicated in moderate and severe renal impairment since its FDA approval in patients with normal renal function or mild renal insufficiency to minimize the potential for toxic metformin levels and MALA. However, the reported incidence of lactic acidosis in clinical practice has proved to be very low (<10 cases per 100,000 patient-years). Several groups have suggested that current renal function cutoffs for metformin are too conservative, thus depriving a substantial number of type 2 diabetes patients from the potential benefit of metformin therapy. On the other hand, the success of metformin as the first-line diabetes therapy may be a direct consequence of conservative labeling, the absence of which could have led to excess patient risk and eventual withdrawal from the market, as happened with earlier biguanide therapies. An investigational delayed-release metformin currently under development could potentially provide a treatment option for patients with renal impairment pending the results of future studies. This literature-based review provides an update on the impact of renal function and other conditions on metformin plasma levels and the risk of MALA in patients with type 2 diabetes.",
keywords = "Drug mechanism, Lactic acidosis, MALA, Metformin, Renal impairment",
author = "Defronzo, {Ralph A} and Fleming, {G. Alexander} and Kim Chen and Bicsak, {Thomas A.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.metabol.2015.10.014",
language = "English (US)",
volume = "65",
pages = "20--29",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Metformin-associated lactic acidosis

T2 - Current perspectives on causes and risk

AU - Defronzo, Ralph A

AU - Fleming, G. Alexander

AU - Chen, Kim

AU - Bicsak, Thomas A.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Although metformin has become a drug of choice for the treatment of type 2 diabetes mellitus, some patients may not receive it owing to the risk of lactic acidosis. Metformin, along with other drugs in the biguanide class, increases plasma lactate levels in a plasma concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver. Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin-associated lactic acidosis (MALA). As these secondary events may be unpredictable and the mortality rate for MALA approaches 50%, metformin has been contraindicated in moderate and severe renal impairment since its FDA approval in patients with normal renal function or mild renal insufficiency to minimize the potential for toxic metformin levels and MALA. However, the reported incidence of lactic acidosis in clinical practice has proved to be very low (<10 cases per 100,000 patient-years). Several groups have suggested that current renal function cutoffs for metformin are too conservative, thus depriving a substantial number of type 2 diabetes patients from the potential benefit of metformin therapy. On the other hand, the success of metformin as the first-line diabetes therapy may be a direct consequence of conservative labeling, the absence of which could have led to excess patient risk and eventual withdrawal from the market, as happened with earlier biguanide therapies. An investigational delayed-release metformin currently under development could potentially provide a treatment option for patients with renal impairment pending the results of future studies. This literature-based review provides an update on the impact of renal function and other conditions on metformin plasma levels and the risk of MALA in patients with type 2 diabetes.

AB - Although metformin has become a drug of choice for the treatment of type 2 diabetes mellitus, some patients may not receive it owing to the risk of lactic acidosis. Metformin, along with other drugs in the biguanide class, increases plasma lactate levels in a plasma concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver. Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin-associated lactic acidosis (MALA). As these secondary events may be unpredictable and the mortality rate for MALA approaches 50%, metformin has been contraindicated in moderate and severe renal impairment since its FDA approval in patients with normal renal function or mild renal insufficiency to minimize the potential for toxic metformin levels and MALA. However, the reported incidence of lactic acidosis in clinical practice has proved to be very low (<10 cases per 100,000 patient-years). Several groups have suggested that current renal function cutoffs for metformin are too conservative, thus depriving a substantial number of type 2 diabetes patients from the potential benefit of metformin therapy. On the other hand, the success of metformin as the first-line diabetes therapy may be a direct consequence of conservative labeling, the absence of which could have led to excess patient risk and eventual withdrawal from the market, as happened with earlier biguanide therapies. An investigational delayed-release metformin currently under development could potentially provide a treatment option for patients with renal impairment pending the results of future studies. This literature-based review provides an update on the impact of renal function and other conditions on metformin plasma levels and the risk of MALA in patients with type 2 diabetes.

KW - Drug mechanism

KW - Lactic acidosis

KW - MALA

KW - Metformin

KW - Renal impairment

UR - http://www.scopus.com/inward/record.url?scp=84959528193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959528193&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2015.10.014

DO - 10.1016/j.metabol.2015.10.014

M3 - Article

VL - 65

SP - 20

EP - 29

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 2

ER -